Actively Recruiting
Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Led by Haisco Pharmaceutical Group Co., Ltd. · Updated on 2024-12-20
47
Participants Needed
1
Research Sites
125 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multicenter, open-label study to evaluate the long-term safety, tolerability and efficacy of HSK39297. Adult patients with PNH who had previously received and completed HSK39297 study treatment will be included. Eligible subjects can maintain HSK39297 treatment until the end of the study.
CONDITIONS
Official Title
Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with PNH who have previously received and completed HSK39297 treatment and are judged by researchers to benefit from continued treatment
- Understand the study procedures and voluntarily agree to participate
You will not qualify if you...
- Hereditary or acquired complement deficiency
- Active primary or secondary immunodeficiency
- History of splenectomy, bone marrow/hematopoietic stem cell or solid organ transplants
- History of recurrent invasive infections from encapsulated organisms or Mycobacterium tuberculosis
- History of serious comorbidities unsuitable for study participation
- Pregnant or lactating women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Actively Recruiting
Research Team
L
Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here